Brind.
  1. A company is conducting clinical trials and seeking drug approval for the U.S. market under the FDA.
  2. Palvella Therapeutics is seeking FDA approval for therapies developed using SELVA and Toiva trials.

SELVA is a clinical trial for QTORIN™ rapamycin.

2 reports, 1 independent Updated Jul 28
Gone quiet
Reports
2
Developments
1
Repetition
50%

New informationRepeats or wire copies

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

SELVA is a clinical trial for QTORIN™ rapamycin.

Who's involved

What this event is mainly about
SELVA

Keep exploring

Part of

Palvella Therapeutics is seeking FDA approval for therapies developed using SELVA and Toiva trials. All 1 developments

Within A company is conducting clinical trials and seeking drug approval for the U.S. market under the FDA.

The entities involved

  • SELVA

    nonprofit organization in Bogotá, Colombia

    Nothing else this week.

Coverage

Newest first; wire copies grouped
  • GlobeNewswirePalvella Therapeutics to Host Second Quarter 2025 Financial Results and Corporate Update Conference Call on August 14, 2025 WAYNE, Pa., Aug. 07, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: PVLA) Palvella Thera
1 more outlet ran the same wire story